Preliminary efficacy results from an ongoing phase I/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced/metastatic solid tumors.
Authors: Jianan Jin, Jun Yao, Mingxi Wang, Huan Zhou, Qiming Wang, Tao Sun, Jie Lin, Lin Wu, Jing Yang, Jin Miao, Yuan Mi, Haiping Wu, Shuning Xing, Zhengbo Song